
Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
Clinical TrialsNeflamapimod Delivers Clinical and Biomarker Benefits in Dementia with Lewy Bodies: Key Findings from the Phase 2b RewinD-LB TrialDementia with Lewy bodies (DLB) is a common type of neurodegenerative dementia. It is marked by fluctuating cognition, visual hallucinations, Parkinsonian movement symptoms, and early problems with attention.…Fact-Checked
Clinical TrialsValbenazine from KINECT-PRO Study Delivers Superior Well-Being Results for Tardive Dyskinesia: Post-Marketing Data from MDS Congress 2025Tardive dyskinesia (TD) remains a persistent movement disorder affecting patients exposed to long-term antipsychotic medications and other dopamine antagonists.Fact-Checked
Clinical TrialsWHO Launches Global Clinical Trials Forum to Boost Worldwide Health ResearchOn 7 October 2025, the World Health Organization officially launched the Global Clinical Trials Forum (GCTF), an initiative aimed at raising global standards for clinical research, harmonizing practices…Fact-Checked
New Drug ApprovalFDA Clears Simponi (Golimumab) for Children with Ulcerative ColitisThe U.S. Food and Drug Administration (FDA) has approved Simponi (Golimumab) for the treatment of children aged two years and older with moderately to severely active ulcerative colitis…Fact-Checked
New Drug ApprovalJascayd (Nerandomilast) Receives FDA Nod for Idiopathic Pulmonary FibrosisThe U.S. Food and Drug Administration (FDA) have approved Jascayd (Nerandomilast) tablets for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.Fact-Checked
Clinical TrialsFDA Approves Arcutis’ Zoryve (Roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5On October 3, 2025, the U.S. Food and Drug Administration (FDA) approved Zoryve® (roflumilast) Cream 0.05%, developed by Arcutis Biotherapeutics, Inc., for the treatment of mild to moderate…Fact-Checked
ResearchJAMA Study Finds Asthma Inhalers Have a Carbon Footprint Equal to 530,000 Cars a YearInhalers play a central role in managing asthma and chronic obstructive pulmonary disease (COPD).Fact-Checked
ResearchWhat Is Wockhardt’s New Drug Zidebactam? A Groundbreaking Beta-Lactam Enhancer in the Fight against SuperbugsZAYNICH, also known as WCK-5222, is a novel antibiotic researched and developed by the Indian pharmaceutical company Wockhardt as a strategic response to the growing global crisis of…Fact-Checked
Research2025 Nobel Prize in Physiology or Medicine: Pioneering Discoveries in Immune Tolerance and Regulatory T CellsThe Nobel Prize in Physiology or Medicine 2025 was awarded jointly to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their pioneering discoveries concerning peripheral immune tolerance…Fact-Checked
ResearchRethinking Lithium: A Potential Therapeutic Avenue in Alzheimer’s diseaseDefence Services Medical Research Centre, Naypyitaw, Myanmar…Fact-Checked
Clinical TrialsFDA Fast Tracks ETX‑636: New Hope for PIK3CA-Mutant Advanced Breast CancerEnsem Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug ETX-636 for the treatment of PIK3CA-mutant, hormone…Fact-Checked
Clinical TrialsPositive Phase 2b Results of Enanta’s Zelicapavir in High-Risk Adults with RSV: A Promising Advancement in Antiviral TherapyEnanta Pharmaceuticals recently announced highly encouraging Phase 2b clinical trial results for zelicapavir, an investigational oral antiviral drug, in treating respiratory syncytial virus (RSV) infection in high-risk adult…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.